Literature DB >> 35657404

Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.

Bo-Jung Chen1,2, Chang-Tsu Yuan3,4,5, Ching-Fen Yang6,7, Chung-Han Ho8,9, Yen-Kuang Lin10,11, Ying-Zhen Su12, Hsiu-Chu Chou13, Shih-Sung Chuang14.   

Abstract

Plasmablastic myeloma (PBM) is a blastic morphologic variant of plasma cell myeloma with less favorable prognosis than those with non-blastic morphology. PBM is rare, without clear-cut definition and detailed clinicopathologic features in the literature. PBM may mimic plasmablastic lymphoma (PBL) as they share nearly identical morphology and immunophenotype. Using the criteria of ≥ 30% plasmablasts in tissue sections, we retrospectively recruited PBM cases and analyzed their clinical, imaging, and pathologic findings, with emphasis on extramedullary involvement. We performed immunohistochemistry, in situ hybridization for Epstein-Barr virus (EBER), and fluorescence in situ hybridization (FISH) for lymphoma- and myeloma-associated genetic alterations. Of the 25 recruited cases, 15 (60%) had extramedullary involvement, which occurred as initial presentation in nine cases. The most common extramedullary sites were soft tissue and/or skin (10/15, 67%), followed by pleural effusion, the lungs, and lymph nodes. Immunohistochemically, tumor cells expressed MYC (74%; 17/23), CD56 (56%; 14/25), and cyclin D1 (16%; 4/25), while CD117 was all negative (n = 25). Of the 20 cases stained with p53, four (20%) cases were diffusely positive, and the remaining 16 cases showed a heterogeneous pattern. EBER was negative in all 24 cases examined. Of the 13 cases examined with FISH, the genetic aberrations identified included del(13q14)(92%; 12/13), gain of chromosome 1q (90%; 9/10), loss of chromosome 1p (60%; 6/10), IGH-FGFR3 reciprocal translocation (23%; 3/13), rearranged MYC (15%; 2/13), and rearranged CCND1 (8%; 1/13), while there were no cases with TP53 deletion (n = 10) or rearrangement of BCL2 (n = 13) or BCL6 (n = 13). The prognosis was dismal regardless of the presence or absence of extramedullary involvement. In conclusion, PBM in Taiwan frequently presented as extramedullary and extranodal lesions, particularly in soft tissue and/or skin, mimicking PBL. FISH for targeted genetic alterations such as del(13q14), gain of chromosome 1q, loss of chromosome 1p, and IGH-FGFR3 might be helpful for the differential diagnoses. Larger studies are warranted to investigate the genetic alterations between PBM and PBL.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Del(13q14); Extramedullary; IGH-FGFR3 reciprocal translocation; Plasmablastic lymphoma; Plasmablastic myeloma

Mesh:

Year:  2022        PMID: 35657404     DOI: 10.1007/s00428-022-03342-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.535


  35 in total

1.  Clinicopathological features of plasmablastic multiple myeloma: a population-based cohort.

Authors:  Hanne E H Møller; Birgitte S Preiss; Per Pedersen; Ida B Kristensen; Charlotte T Hansen; Mikael Frederiksen; Niels Abildgaard; Michael B Møller
Journal:  APMIS       Date:  2015-07-08       Impact factor: 3.205

2.  BRAF V600E mutation and clonal evolution in a patient with relapsed refractory myeloma with plasmablastic differentiation.

Authors:  Olga L Bohn; Katharine Hsu; David M Hyman; Daniela S Pignataro; Sergio Giralt; Julie Teruya-Feldstein
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-17

3.  Histologic classification and staging of multiple myeloma. A retrospective and prospective study of 674 cases.

Authors:  R Bartl; B Frisch; A Fateh-Moghadam; G Kettner; K Jaeger; W Sommerfeld
Journal:  Am J Clin Pathol       Date:  1987-03       Impact factor: 2.493

Review 4.  International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

Authors:  S Vincent Rajkumar; Meletios A Dimopoulos; Antonio Palumbo; Joan Blade; Giampaolo Merlini; María-Victoria Mateos; Shaji Kumar; Jens Hillengass; Efstathios Kastritis; Paul Richardson; Ola Landgren; Bruno Paiva; Angela Dispenzieri; Brendan Weiss; Xavier LeLeu; Sonja Zweegman; Sagar Lonial; Laura Rosinol; Elena Zamagni; Sundar Jagannath; Orhan Sezer; Sigurdur Y Kristinsson; Jo Caers; Saad Z Usmani; Juan José Lahuerta; Hans Erik Johnsen; Meral Beksac; Michele Cavo; Hartmut Goldschmidt; Evangelos Terpos; Robert A Kyle; Kenneth C Anderson; Brian G M Durie; Jesus F San Miguel
Journal:  Lancet Oncol       Date:  2014-10-26       Impact factor: 41.316

5.  CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma.

Authors:  Etan Marks; Yang Shi; Yanhua Wang
Journal:  Histopathology       Date:  2017-04-11       Impact factor: 5.087

6.  IgG4 plasma cell myeloma: new insights into the pathogenesis of IgG4-related disease.

Authors:  Julia T Geyer; Ruben Niesvizky; David S Jayabalan; Susan Mathew; Shivakumar Subramaniyam; Alexander I Geyer; Attilio Orazi; Scott A Ely
Journal:  Mod Pathol       Date:  2013-09-13       Impact factor: 7.842

7.  Aggressive presentation of plasmablastic myeloma.

Authors:  Jaime Andres Suarez-Londono; Abhinav Rohatgi; Crystal Antoine-Pepeljugoski; Marc J Braunstein
Journal:  BMJ Case Rep       Date:  2020-04-06

8.  Rare case of plasmablastic myeloma diagnosed on lung biopsy.

Authors:  Benjamin Ayeboa-Sallah; Saad Qutab; Richard Grace; Neel Sharma
Journal:  BMJ Case Rep       Date:  2021-03-19

9.  Genetic Basis of Extramedullary Plasmablastic Transformation of Multiple Myeloma.

Authors:  Ying Liu; Fatima Jelloul; Yanming Zhang; Tapan Bhavsar; Caleb Ho; Mamta Rao; Natasha E Lewis; Robert Cimera; Jeeyeon Baik; Allison Sigler; Filiz Sen; Mariko Yabe; Mikhail Roshal; Ola Landgren; Ahmet Dogan; Wenbin Xiao
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.298

10.  Duodenal localization of plasmablastic myeloma.

Authors:  Stefano Licci
Journal:  World J Gastrointest Pathophysiol       Date:  2017-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.